{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:03:52Z","timestamp":1787943832823,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12185-025-04111-z","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:03:23Z","timestamp":1763373803000},"page":"332-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of venetoclax-based regimens versus intensive chemotherapy in older adults with newly diagnosed acute myeloid leukemia: a single-center retrospective study"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0923-0784","authenticated-orcid":false,"given":"Tomohito","family":"Shimada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takahata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"3","key":"4111_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(3):502\u201326. https:\/\/doi.org\/10.1002\/ajh.26822.","journal-title":"Am J Hematol"},{"key":"4111_CR2","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","volume":"102","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, et al. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023;102:749\u201354.","journal-title":"Ann Hematol"},{"key":"4111_CR3","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","volume":"119","author":"G Juliusson","year":"2012","unstructured":"Juliusson G, Lazarevic V, H\u00f6rstedt A-S, Hagberg O, H\u00f6glund M, Swedish Acute Leukemia Registry Group. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119:3890\u20139.","journal-title":"Blood"},{"key":"4111_CR4","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","volume":"120","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120:4840\u20135.","journal-title":"Blood"},{"key":"4111_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"4111_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ejh.14278","volume":"113","author":"F Acker","year":"2024","unstructured":"Acker F, Chromik J, Tiedjen E, Wolf S, Vischedyk JB, Makowka P, et al. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy. Eur J Haematol. 2024;113(5):623\u201330. https:\/\/doi.org\/10.1111\/ejh.14278.","journal-title":"Eur J Haematol"},{"issue":"2","key":"4111_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3324\/haematol.2022.280802","volume":"108","author":"S Jaramillo","year":"2023","unstructured":"Jaramillo S, Schlenk RF. Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica. 2023;108(2):342\u201352. https:\/\/doi.org\/10.3324\/haematol.2022.280802.","journal-title":"Haematologica"},{"issue":"24","key":"4111_CR8","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565\u201373. https:\/\/doi.org\/10.1182\/bloodadvances.2021005538.","journal-title":"Blood Adv"},{"key":"4111_CR9","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.26991","volume":"98","author":"AH Matthews","year":"2023","unstructured":"Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, et al. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023;98:1254\u201364.","journal-title":"Am J Hematol"},{"issue":"3","key":"4111_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","volume":"96","author":"A Maiti","year":"2021","unstructured":"Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021;96(3):282\u201391. https:\/\/doi.org\/10.1002\/ajh.26061.","journal-title":"Am J Hematol"},{"key":"4111_CR11","doi-asserted-by":"crossref","unstructured":"Solana-Altabella A, Rodr\u00edguez-Veiga R, Mart\u00ednez-Cuadr\u00f3n D, Montesinos P. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? Ann Hematol. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/39150561\/. Accessed 13 Jan 2025","DOI":"10.1007\/s00277-024-05891-w"},{"key":"4111_CR12","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"4111_CR13","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;117:2366\u201372.","journal-title":"Blood"},{"key":"4111_CR14","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"4111_CR15","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"4111_CR16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"4111_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4111_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99(4):615\u201324. https:\/\/doi.org\/10.1002\/ajh.27246.","journal-title":"Am J Hematol"},{"issue":"1","key":"4111_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyab170","volume":"52","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, et al. Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Jpn J Clin Oncol. 2022;52(1):29\u201338. https:\/\/doi.org\/10.1093\/jjco\/hyab170.","journal-title":"Jpn J Clin Oncol"},{"key":"4111_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000531628","volume":"146","author":"JH Choi","year":"2023","unstructured":"Choi JH, Shukla M, Abdul-Hay M. Acute myeloid leukemia treatment in the elderly: a comprehensive review of the present and future. Acta Haematol. 2023;146:431\u201357.","journal-title":"Acta Haematol"},{"key":"4111_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","volume":"28","author":"A Maiti","year":"2022","unstructured":"Maiti A, Konopleva MY. How we incorporate venetoclax in treatment regimens for acute myeloid leukemia. Cancer J. 2022;28:2\u201313.","journal-title":"Cancer J"},{"key":"4111_CR22","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102:541\u20136.","journal-title":"Ann Hematol"},{"key":"4111_CR23","doi-asserted-by":"crossref","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol. 2024;99:E63\u20136.","DOI":"10.1002\/ajh.27180"},{"key":"4111_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-025-01324-7","volume":"15","author":"M Kanaya","year":"2025","unstructured":"Kanaya M, Onozawa M, Matsukawa T, Miyashita N, Fujii F, Yoshida S, et al. Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net. Blood Cancer J. 2025;15:118.","journal-title":"Blood Cancer J"},{"key":"4111_CR25","first-page":"135","volume":"65","author":"Y Osada","year":"2024","unstructured":"Osada Y, Kanai-Sudo H, Mizuki T, Tanosaki S, Suzuki K. Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy). Rinsho Ketsueki. 2024;65:135\u201341.","journal-title":"Rinsho Ketsueki"},{"issue":"1","key":"4111_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ajh.27515","volume":"100","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Ill\u00e9s \u00c1, et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2025;100(1):185\u20138. https:\/\/doi.org\/10.1002\/ajh.27515.","journal-title":"Am J Hematol"},{"key":"4111_CR27","unstructured":"Wei AH, Loo S, Daver NG. How I Treat patients with AML using azacitidine and venetoclax. Blood. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/39316723\/. Accessed 15 Mar 2025"},{"key":"4111_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39:359\u201367.","journal-title":"Clin Ther"},{"key":"4111_CR29","doi-asserted-by":"publisher","first-page":"2433172","DOI":"10.1080\/16078454.2024.2433172","volume":"29","author":"X Zhong","year":"2024","unstructured":"Zhong X, Wang J, Dai Y, Huang X, Liu J, Xiang B, et al. Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia. Hematology. 2024;29:2433172.","journal-title":"Hematology"},{"key":"4111_CR30","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/bjh.19670","volume":"205","author":"B Weinbergerov\u00e1","year":"2024","unstructured":"Weinbergerov\u00e1 B, Mayer J, Kabut T, Sperr WR, \u0160tevkov\u00e1 J, Jon\u00e1\u0161ov\u00e1 A, et al. Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis. Br J Haematol. 2024;205:1746\u201350.","journal-title":"Br J Haematol"},{"issue":"8","key":"4111_CR31","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1080\/10428194.2022.2047964","volume":"63","author":"EC Chen","year":"2022","unstructured":"Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022;63(8):1934\u201341. https:\/\/doi.org\/10.1080\/10428194.2022.2047964.","journal-title":"Leuk Lymphoma"},{"key":"4111_CR32","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"issue":"2","key":"4111_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99(2):193\u2013202. https:\/\/doi.org\/10.1002\/ajh.27138.","journal-title":"Am J Hematol"},{"key":"4111_CR34","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024;144:2211\u201322.","journal-title":"Blood"},{"issue":"4","key":"4111_CR35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.27231","volume":"99","author":"Y Abaza","year":"2024","unstructured":"Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, et al. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers. Am J Hematol. 2024;99(4):606\u201314. https:\/\/doi.org\/10.1002\/ajh.27231.","journal-title":"Am J Hematol"},{"key":"4111_CR36","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, et al. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021;106:894\u20138.","journal-title":"Haematologica"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04111-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04111-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04111-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:10:53Z","timestamp":1772889053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04111-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4111"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04111-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}